Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ZFGN Zafgen (ZFGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Zafgen Stock (NASDAQ:ZFGN) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Zafgen alerts:Sign Up Key Stats Today's Range$7.63▼$8.3650-Day Range$0.99▼$25.0652-Week Range$0.62▼$2.76Volume431,681 shsAverage Volume360,199 shsMarket Capitalization$290.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.Read More… Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Receive ZFGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zafgen and its competitors with MarketBeat's FREE daily newsletter. Email Address ZFGN Stock News HeadlinesTokyo Steel Manufacturing Co Ltd 5423May 16, 2024 | morningstar.comGlobal Weight Loss Therapeutics Professional Market 2023 (Exclusive Report) | Future Work Trend by 2030April 9, 2023 | marketwatch.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…November 2, 2024 | Porter & Company (Ad)Zafgen (ZFGN) Stock Skyrockets on Positive Obesity Drug ResultsFebruary 26, 2023 | thestreet.comZafgen (ZFGN) Stock Surges on Positive Obesity Drug TrialJanuary 13, 2023 | thestreet.comFood and drink in a castleNovember 8, 2022 | bbc.co.ukLRMR Larimar Therapeutics, Inc.September 30, 2022 | seekingalpha.comForm 424B5 Larimar Therapeutics, - StreetInsider.comSeptember 14, 2022 | streetinsider.comSee More Headlines ZFGN Stock Analysis - Frequently Asked Questions How were Zafgen's earnings last quarter? Zafgen Inc (NASDAQ:ZFGN) released its quarterly earnings data on Thursday, March, 5th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.19). What other stocks do shareholders of Zafgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zafgen investors own include Xtrackers California Municipal Bond ETF (CA), Bristol-Myers Squibb (BMY), Endologix (ELGX), Energy Transfer (ET), BlackRock (BLK), TG Therapeutics (TGTX) and SCYNEXIS (SCYX). Company Calendar Last Earnings3/05/2020Today11/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZFGN CUSIPN/A CIK1374690 Webwww.zafgen.com Phone617-622-4003FaxN/AEmployees38Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.34% Return on Assets-34.55% Debt Debt-to-Equity Ratio0.26 Current Ratio6.56 Quick Ratio6.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book5.73Miscellaneous Outstanding Shares37,470,000Free FloatN/AMarket Cap$290.02 million OptionableNot Optionable Beta0.27 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ZFGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.